August 21, 2025Diabetes/Metabolism Research and Reviews

Early Efficacy and Safety of Finerenone on Type 2 Diabetes‐Related Chronic Kidney Disease: A Real‐World Observational Study in China

View Full Paper

Ask AI

Bookmark

Authors

LLLiyu LinGuangzhou University of Chinese Medicine ZSZiyan ShenShanghai Medical College of Fudan University ZCZhi Hong ChenNational Taiwan Normal University

Discussion

Member takes

Implication

Observational study shows finerenone reduces albuminuria in diabetic CKD patients, highlighting the need for monitoring renal function and potassium levels.

Key Points

Finerenone significantly lowered urinary albumin/creatinine ratio by 39.55% in patients with type 2 diabetes-related CKD, indicating its efficacy.
After 12 weeks, 61.9% of patients showed a decline in eGFR of over 10%, with careful monitoring recommended for renal function.
The observational study included 105 patients with type 2 diabetes-related CKD initiating finerenone therapy, assessing key health parameters.
Monitoring for hyperkalemia is critical, particularly in patients with baseline eGFR less than 60 mL/min/1.73 m², where the incidence reached 37.5%.

Cite This Study

Lin et al. (2025) studied this question.

synapsesocial.com/papers/68af6d907567bf4f94feaf0e https://doi.org/10.1002/dmrr.70078

View Full Paper

Ask AI

Bookmark

Implication

Observational study shows finerenone reduces albuminuria in diabetic CKD patients, highlighting the need for monitoring renal function and potassium levels.

Early Efficacy and Safety of Finerenone on Type 2 Diabetes‐Related Chronic Kidney Disease: A Real‐World Observational Study in China

Discussion

Member takes

Implication

Key Points

Cite This Study

Early Efficacy and Safety of Finerenone on Type 2 Diabetes‐Related Chronic Kidney Disease: A Real‐World Observational Study in China

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider